Fresh analysis suggests that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who end traditional diet and exercise programs.
Research printed in a leading health publication demonstrates that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People buying such medications should be informed of the risk of rapid rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight within about a year and a half.
Analyzing Approaches
The research, which examined dozens of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with older methods.
The team note that individuals who lose weight through diet and exercise generally have a more gradual creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Nutrition scientists suggest the mode of action of the drugs explains the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
The NHS suggest the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts argue that, considering the significant potential of relapse, the treatment is often ongoing.
This view is supported by pharmaceutical companies, who note that the results "underscore the long-term character of obesity," similar to managing diseases like diabetes.
Patient Experiences
People who have stopped the medication describe a powerful resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly starving," recalled a patient.
The struggle is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Use
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is more common among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on ongoing behavioural management.
